{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:41:47Z","timestamp":1761561707117,"version":"3.40.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T00:00:00Z","timestamp":1354665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s40273-012-0009-2","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T21:13:39Z","timestamp":1355778819000},"page":"63-75","source":"Crossref","is-referenced-by-count":11,"title":["Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B"],"prefix":"10.1007","volume":"31","author":[{"given":"Mar\u00eda","family":"Buti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,5]]},"reference":[{"key":"9_CR1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"D Ganem","year":"2004","unstructured":"Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med. 2004;350:1118\u201329.","journal-title":"N Engl J Med"},{"key":"9_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"ASF Lok","year":"2007","unstructured":"Lok ASF, McMahon BJ. Chronic hepatitis B: AASLD practice guidelines. Hepatology. 2007;45:507\u201339.","journal-title":"Hepatology"},{"key":"9_CR3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","volume":"45","author":"JH Hoofnagle","year":"2007","unstructured":"Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056\u201375.","journal-title":"Hepatology"},{"key":"9_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","volume":"50","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227\u201342.","journal-title":"J Hepatol"},{"key":"9_CR5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.","journal-title":"JAMA"},{"key":"9_CR6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","volume":"37","author":"H Mommeja-Marin","year":"2003","unstructured":"Mommeja-Marin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37:1309\u201319.","journal-title":"Hepatology"},{"key":"9_CR7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"3","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;3:263\u201383.","journal-title":"Hepatol Int"},{"key":"9_CR8","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1097\/00004836-200411003-00009","volume":"38","author":"R Brown","year":"2004","unstructured":"Brown R, Cock E, Colin X, et al. Hepatitis B management costs in France, Italy, Spain and the United Kingdom. J Clin Gastroenterol. 2004;38:S169\u201374.","journal-title":"J Clin Gastroenterol"},{"key":"9_CR9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MEG.0b013e3282f340c8","volume":"20","author":"BI Idris","year":"2008","unstructured":"Idris BI, Brosa M, Richardus JH, et al. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol. 2008;20:320\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2010.00115","volume":"1","author":"S Simoens","year":"2010","unstructured":"Simoens S. How to assess the value of medicines? Front Pharmacol. 2010;1:115.","journal-title":"Front Pharmacol"},{"issue":"Suppl. 1","key":"9_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0213-9111(11)70005-X","volume":"25","author":"A Garc\u00eda-Alt\u00e9s","year":"2011","unstructured":"Garc\u00eda-Alt\u00e9s A, Navas E, Soriano MA. Economic evaluation of public health interventions [in Spanish]. Gac Sanit. 2011;25(Suppl. 1):25\u201331.","journal-title":"Gac Sanit"},{"issue":"5","key":"9_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11593380-000000000-00000","volume":"9","author":"MJ Ijzerman","year":"2011","unstructured":"Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl Health Econ Health Policy. 2011;9(5):331\u201347.","journal-title":"Appl Health Econ Health Policy"},{"key":"9_CR13","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. York: University of York; 2008. http:\/\/www.york.ac.uk\/inst\/crd\/pdf\/Systematic_Reviews.pdf . Accessed 29 Sept 2011."},{"key":"9_CR14","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.","edition":"3"},{"issue":"4","key":"9_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF03256136","volume":"6","author":"E Arnold","year":"2008","unstructured":"Arnold E, Yuan Y, Iloeje U, et al. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy. 2008;6(4):231\u201346.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"9_CR16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jhep.2009.04.013","volume":"51","author":"M Buti","year":"2009","unstructured":"Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. 2009;51(4):640\u20136.","journal-title":"J Hepatol"},{"issue":"1","key":"9_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CEOR.S16655","volume":"3","author":"GL Colombo","year":"2011","unstructured":"Colombo GL, Gaeta GB, Vigano M, et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clin Outcomes Res. 2011;3(1):37\u201346.","journal-title":"Clin Outcomes Res"},{"issue":"5","key":"9_CR18","first-page":"368","volume":"12","author":"AM Costa","year":"2008","unstructured":"Costa AM, L \u2018italien G, Nita ME, et al. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. Braz J Infect Dis. 2008;12(5):368\u201373.","journal-title":"Braz J Infect Dis"},{"issue":"8","key":"9_CR19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1524-4733.2010.00782.x","volume":"13","author":"H Dakin","year":"2010","unstructured":"Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13(8):922\u201333.","journal-title":"Value Health"},{"issue":"12","key":"9_CR20","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2165\/11589260-000000000-00000","volume":"29","author":"H Dakin","year":"2011","unstructured":"Dakin H, Sherman M, Fung S, et al. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. Pharmacoeconomics. 2011;29(12):1075\u201391.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"9_CR21","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/j.1572-0241.2006.00769.x","volume":"101","author":"F Kanwal","year":"2006","unstructured":"Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006;101(9):2076\u201389.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"9_CR22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3851\/IMP1496","volume":"15","author":"YY Lui","year":"2010","unstructured":"Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther. 2010;15(2):145\u201355.","journal-title":"Antivir Ther"},{"issue":"3\u20134","key":"9_CR23","first-page":"20","volume":"4","author":"E Orlewska","year":"2008","unstructured":"Orlewska E, Zammit D, Yuan Y, et al. The cost-effectiveness analysis of entecavir in the treatment of chronic hepatitis B (CHB) patients in Poland. Exp Clin Hepatol. 2008;4(3\u20134):20\u20138.","journal-title":"Exp Clin Hepatol"},{"key":"9_CR24","unstructured":"Schwierz C, Thiry N, Van de Sande S, et al. Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium: part 2 [KCE reports 157B]. Brussels: Belgian Health Care Knowledge Centre (KCE); 2011. http:\/\/test.kce.fgov.be\/sites\/default\/files\/page_documents\/kce_157b_h%C3%A9patite%20b_chronique_tome%202.pdf . Accessed 10 Oct 2011."},{"issue":"11","key":"9_CR25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/00019053-200826110-00006","volume":"26","author":"DE Spackman","year":"2008","unstructured":"Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26(11):937\u201349.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"9_CR26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2165\/00019053-200725110-00006","volume":"25","author":"DL Veenstra","year":"2007","unstructured":"Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25(11):963\u201377.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"9_CR27","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2036.2008.03691.x","volume":"27","author":"DL Veenstra","year":"2008","unstructured":"Veenstra DL, Spackman DE, Di Bisceglie A, et al. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2008;27(12):1240\u201352.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9_CR28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1524-4733.2010.00733.x","volume":"13","author":"B Wu","year":"2010","unstructured":"Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13(5):592\u2013600.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"9_CR29","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1111\/j.1524-4733.2008.00362.x","volume":"11","author":"Y Yuan","year":"2008","unstructured":"Yuan Y, Iloeje U, Li H, et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health. 2008;11(Suppl 1):S11\u201322.","journal-title":"Value Health"},{"issue":"1","key":"9_CR30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18553\/jmcp.2008.14.1.21","volume":"14","author":"Y Yuan","year":"2008","unstructured":"Yuan Y, Iloeje UH, Hay J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm. 2008;14(1):21\u201333.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"9_CR31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","volume":"11","author":"AR Levy","year":"2008","unstructured":"Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527\u201338.","journal-title":"Value Health"},{"key":"9_CR32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001\u201310.","journal-title":"N Engl J Med"},{"key":"9_CR33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011\u201320.","journal-title":"N Engl J Med"},{"key":"9_CR34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.","journal-title":"JAMA"},{"key":"9_CR35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang SI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678\u201386.","journal-title":"Gastroenterology"},{"issue":"8","key":"9_CR36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1524-4733.2010.00777.x","volume":"13","author":"H Dakin","year":"2010","unstructured":"Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13(8):934\u201345.","journal-title":"Value Health"},{"key":"9_CR37","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442\u201355.","journal-title":"N Engl J Med"},{"key":"9_CR38","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/gast.2002.37058","volume":"123","author":"CL Lai","year":"2002","unstructured":"Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123:1831\u20138.","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"9_CR39","first-page":"192","volume":"42","author":"HC Thomas","year":"2005","unstructured":"Thomas HC, Manns PM, Gish RG, et al. Decline in serum HBV DNA and ALT normalization is associated with histological response among nucleoside na\u00efve patients in entecavir phase III trials. J Hepatol. 2005;42(Suppl 2):192\u20133.","journal-title":"J Hepatol"},{"key":"9_CR40","first-page":"77","volume":"21","author":"G Fattovich","year":"1995","unstructured":"Fattovich G, Giustina G, Schalm S, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology. 1995;21:77\u201382.","journal-title":"Hepatology"},{"key":"9_CR41","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u201331.","journal-title":"N Engl J Med"},{"key":"9_CR42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0016-5085(84)90406-2","volume":"86","author":"GL Davis","year":"1984","unstructured":"Davis GL, Hoofnagle JH. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 1984;86:230\u20135.","journal-title":"Gastroenterology"},{"key":"9_CR43","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","volume":"53","author":"HLY Chan","year":"2004","unstructured":"Chan HLY, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494\u20138.","journal-title":"Gut"},{"key":"9_CR44","unstructured":"Heathcote EJ, Gane EJ, de Man RA, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis [abstract no. 158]. In: 59th Annual Meeting of the American Association for the Study of Liver Diseases. 31 Oct\u20134 Nov 2008. San Francisco."},{"key":"9_CR45","unstructured":"Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102) [abstract no. 146]. In: 59th Annual Meeting of the American Association for the Study of Liver Diseases. 31 Oct\u20134 Nov 2008. San Francisco."},{"issue":"5","key":"9_CR46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","volume":"133","author":"RG Gish","year":"2007","unstructured":"Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96\u00a0weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437\u201344.","journal-title":"Gastroenterology"},{"issue":"3","key":"9_CR47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12072-007-9009-2","volume":"1","author":"G Yao","year":"2007","unstructured":"Yao G, Chen C, Lu W, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-na\u00efve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1(3):365\u20137.","journal-title":"Hepatol Int"},{"issue":"2","key":"9_CR48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2008.10.017","volume":"50","author":"D Shouval","year":"2009","unstructured":"Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2009;50(2):289\u201395.","journal-title":"J Hepatol"},{"key":"9_CR49","doi-asserted-by":"crossref","unstructured":"Horsmans Y, Thiry N, le Polain M, et al. Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: literature review and results of a national study [KCE reports 127C]. Brussels: Belgian Health Care Knowledge Centre (KCE); 2010. https:\/\/kce.fgov.be\/sites\/default\/files\/page_documents\/d20101027324.pdf . Accessed 10 Oct 2011.","DOI":"10.57598\/R127C"},{"key":"9_CR50","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678\u201386.","journal-title":"Gastroenterology"},{"key":"9_CR51","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001\u201310.","journal-title":"N Engl J Med"},{"key":"9_CR52","unstructured":"Gish R, Chang T, De Man RA, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96\u00a0weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). In: 56th American Association for the Study of Liver Diseases Annual Meeting; 11\u201315 Nov 2005; San Francisco."},{"key":"9_CR53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","volume":"8","author":"YF Liaw","year":"1988","unstructured":"Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493\u20136.","journal-title":"Hepatology"},{"key":"9_CR54","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","volume":"35","author":"YS Hsu","year":"2002","unstructured":"Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522\u20137.","journal-title":"Hepatology"},{"key":"9_CR55","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","volume":"97","author":"G Fattovich","year":"2002","unstructured":"Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886\u201395.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"9_CR56","first-page":"1083","volume":"25","author":"YT Lin","year":"2004","unstructured":"Lin YT, Liu YH. Epidemiological study of hepatitis B in 1990\u20132003 in Wuxi City, Jiangsu Province [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25(12):1083.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"9_CR57","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMra0801644","volume":"359","author":"JL Dienstag","year":"2008","unstructured":"Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486\u2013500.","journal-title":"N Engl J Med"},{"key":"9_CR58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Nancy L, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263\u201383.","journal-title":"Hepatol Int"},{"key":"9_CR59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jac\/dkm175","volume":"60","author":"G Yao","year":"2007","unstructured":"Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother. 2007;60:201\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"9_CR60","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1440-1746.2007.05068.x","volume":"22","author":"X Sun","year":"2007","unstructured":"Sun X, Qin WX, Li YP, et al. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. J Gastroenterol Hepatol. 2007;22(9):1369\u201377.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"9_CR61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1440-1746.2002.02751.x","volume":"17","author":"PW Angus","year":"2002","unstructured":"Angus PW. Hepatitis B: weighing the costs of treatment. J Gastroenterol Hepatol. 2002;17(7):737\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"9_CR62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.18553\/jmcp.2008.14.1.65","volume":"14","author":"ML Holbrook","year":"2008","unstructured":"Holbrook ML. Cost-effective pharmacologic therapies to treat chronic hepatitis B: how far have we really come? J Manag Care Pharm. 2008;14(1):65\u20139.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"9_CR63","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hec.1486","volume":"19","author":"R Anderson","year":"2010","unstructured":"Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010;19(3):350\u201364.","journal-title":"Health Econ"},{"issue":"1 Suppl","key":"9_CR64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0749-3797(99)00120-8","volume":"18","author":"VG Carande-Kulis","year":"2000","unstructured":"Carande-Kulis VG, Maciosek MV, Briss PA, et al. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services. Am J Prev Med. 2000;18(1 Suppl):75\u201391.","journal-title":"Am J Prev Med"},{"issue":"3","key":"9_CR65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3988\/jcn.2010.6.3.117","volume":"6","author":"KT Jung","year":"2010","unstructured":"Jung KT, Shin DW, Lee KJ, et al. Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review. J Clin Neurol. 2010;6(3):117\u201326.","journal-title":"J Clin Neurol"},{"issue":"3","key":"9_CR66","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3111\/13696998.2010.499813","volume":"13","author":"JA Mauskopf","year":"2010","unstructured":"Mauskopf JA, Baker CL, Monz BU, et al. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ. 2010;13(3):403\u201317.","journal-title":"J Med Econ"},{"issue":"14","key":"9_CR67","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2165\/00003495-200666140-00005","volume":"66","author":"SH Han","year":"2006","unstructured":"Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs. 2006;66(14):1831\u201351.","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"9_CR68","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1111\/j.1524-4733.2010.00751.x","volume":"13","author":"A Briggs","year":"2010","unstructured":"Briggs A. Transportability of comparative effectiveness and cost-effectiveness between countries. Value Health. 2010;13(Suppl. 1):S22\u20135.","journal-title":"Value Health"},{"issue":"5","key":"9_CR69","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10198-010-0253-3","volume":"12","author":"P Vemer","year":"2011","unstructured":"Vemer P, Rutten-van M\u00f6lken MP. Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ. 2011;12(5):397\u2013404.","journal-title":"Eur J Health Econ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-012-0009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-012-0009-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-012-0009-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:15:31Z","timestamp":1745439331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-012-0009-2"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1007\/s40273-012-0009-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}